Word count: 2503 words preliminary data reported so far. However, resistance to some of these therapies has already been noted. The study of circulating tumor cells will likely be important not only to identify patients likely to receive benefit from this therapeutic approach, but also to further understand the molecular mechanisms of resistance.
In patients with castration-resistant prostate cancer (CRPC), androgen receptors (ARs) are likely to be activated by androgens converted from adrenal androgens or synthesized intratumorally via the de novo route. Despite castration, adrenal androgens, dehydroandrostenedione (DHEA) and androstenedione, both of which are synthesized by 17,20-lyase, can be produced in the adrenal glands, from where they can be transported to CRPC tissue and converted to testosterone and dihyrotestosterone (DHT). DHEA and androstenedione can also be synthesized from cholesterol intratumorally in CRPC tissues and converted to testosterone and DHT via the de novo route. The testosterone and DHT can then stimulate androgen receptors (ARs) bound to androgen-responsive elements (AREs), which in turn leads to activation of AR-regulated genes. 17,20-lyase activity is essential for androgen biosynthesis. 17-hydroxylase activity of CYP17A1 is necessary for the synthesis of cortisol. Decreased levels of cortisol by inhibition of 17-hydroxylase, in turn, stimulate the secretion of adrenocorticotropic hormone (ACTH) and ACTH-stimulated steroid synthesis, until the increased corticosterone levels compensate for the decreased levels of cortisol and the total glucocorticoid activity is restored to normal levels. Thus plasma levels of corticosterone and 11-deoxycorticosterone increase in this situation, leading to hypertension. Abiraterone acetate, TAK-700 and TOK-001 inhibit CYP17A1 activity. MDV3100 and TOK-001 inhibited AR transcriptional activity in CRPC unlike bicalutamide.
3B-HSD, 3-beta-hydroxy steroid dehydrogenase; SRD5A, steroid 5α reductase, E1;
